Lab-Engineered Peptide Targets Glioblastoma Stem Cells
Researchers at Virginia Tech developed a lab-designed peptide, JM2, that targets glioblastoma stem cells by disrupting connexin 43's interaction with microtubules, effectively killing these resistant cells in lab tests and slowing tumor growth in animal models, offering a promising approach to prevent tumor recurrence in this aggressive brain cancer.